Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorProchaska, Jürgen H.-
dc.contributor.authorJünger, Claus-
dc.contributor.authorSchulz, Andreas-
dc.contributor.authorArnold, Natalie-
dc.contributor.authorMüller, Felix-
dc.contributor.authorHeidorn, Marc William-
dc.contributor.authorBaumkötter, Rieke-
dc.contributor.authorZahn, Daniela-
dc.contributor.authorKoeck, Thomas-
dc.contributor.authorTröbs, Sven-Oliver-
dc.contributor.authorLackner, Karl J.-
dc.contributor.authorDaiber, Andreas-
dc.contributor.authorBinder, Harald-
dc.contributor.authorShah, Sanjiv J.-
dc.contributor.authorGori, Tommaso-
dc.contributor.authorMünzel, Thomas-
dc.contributor.authorWild, Philipp S.-
dc.description.abstractBackground The sodium-glucose co-transporter 2 inhibitor empagliflozin improves cardiovascular outcome in patients with type 2 diabetes mellitus (T2DM) and heart failure. Experimental studies suggest a direct cardiac effect of empagliflozin associated with an improvement in left ventricular diastolic function. Methods In the randomized, double-blind, two-armed, placebo-controlled, parallel group trial EmDia, patients with T2DM and elevated left ventricular E/E´ ratio were enrolled and randomized 1:1 to receive empagliflozin 10 mg/day versus placebo. The primary endpoint was the change of left ventricular E/E´ ratio after 12 weeks of intervention. Results A total of 144 patients with T2DM and an elevated left ventricular E/e´ ratio (age 68.9 ± 7.7 years; 14.1% women; E/e´ ratio 9.61[8.24/11.14], left ventricular ejection fraction 58.9% ± 5.6%). After 12 weeks of intervention, empagliflozin resulted in a significant higher decrease in the primary endpoint E/e´ ratio by − 1.18 ([95% confidence interval (CI) − 1.72/− 0.65]; P < 0.0001) compared with placebo. The beneficial effect of empagliflozin was consistent across all subgroups and also occurred in subjects with heart failure and preserved ejection fraction (n = 30). Additional effects of empagliflozin on body weight, HbA1c, uric acid, red blood cell count, hemoglobin, mean corpuscular hemoglobin, and hematocrit were detected (all P < 0.001). Approximately one-third of the reduction in E/e´ by empagliflozin could be explained by the variables examined. Conclusions Empagliflozin improves diastolic function in patients with T2DM and elevated end-diastolic pressure. Since the positive effects were consistent in patients with and without heart failure with preserved ejection fraction, the data add a mechanistic insight for the beneficial cardiovascular effect of empagliflozin. Trial registration, unique identifier: NCT02932436.en_GB
dc.rightsCC BY*
dc.subject.ddc610 Medizinde_DE
dc.subject.ddc610 Medical sciencesen_GB
dc.titleEffects of empagliflozin on left ventricular diastolic function in addition to usual care in individuals with type 2 diabetes mellitus : results from the randomized, double-blind, placebo-controlled EmDia trialen_GB
jgu.type.versionPublished versionde
jgu.organisation.departmentFB 04 Medizinde
jgu.organisation.nameJohannes Gutenberg-Universität Mainz-
jgu.journal.titleClinical research in cardiologyde
jgu.journal.volumeVersion of Record (VoR)de
Appears in collections:DFG-491381577-H

Files in This Item:
  File Description SizeFormat
effects_of_empagliflozin_on_l-20230424121207128.pdf1.16 MBAdobe PDFView/Open